Top

News & Events

Novogen Selected to Present at Cavendish Global Health Impact Forum

Novogen Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Sydney, Australia — 10 March 2014 — Novogen Limited (ASX: ‘NRT’; NASDAQ: ‘NVGN’), an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York.  The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. 

To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. 

“With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said Michael Moffat, Cavendish co-founder and President.  “The quality and originality of Novogen’s research and scientific insights in cancer positions them to make a major contribution to the treatment of adult and pediatric cancers.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to treating – and possibly curing – many of the most pervasive and deadly forms of cancer afflicting populations around the world today,” said Graham Kelly, PhD, Novogen CEO and Executive Chairman. “We welcome the chance to interact with many of world’s leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

"Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences,” Mr. Moffat explained.

The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.  Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.


Notes To Editors

About Novogen
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN').  The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.

Further information is available on the Company's website, www.novogen.com

About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (NYC, May 2014), Europe (London, October 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

For more information: www.cavendishglobal.com



Issued for and on behalf of Novogen.

To contact the Novogen team at Instinctif Partners, email novogen@instinctif.com

back to news

People

Sue CharlesManaging Partner